Kane Biotech Inc. (TSXV:KNE)

Kane Biotech Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 2, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	7	15	11	11	18	15
Market Cap Growth	-49.79%	43.41%	-6.12%	-36.87%	17.03%	6.98%
Enterprise Value	9	17	20	19	23	17
Last Close Price	0.04	0.11	0.08	0.09	0.15	0.14
PE Ratio	-	2.48	-	-	-	-
PS Ratio	12.64	7.27	70.80	71.68	11.07	11.33
PB Ratio	-9.16	-9.28	-1.25	-2.71	-11.36	14.15
EV/Sales Ratio	15.00	8.11	136.29	121.77	14.60	12.97
Debt / Equity Ratio	-2.90	-1.33	-1.10	-1.66	-3.01	2.11
Net Debt / Equity Ratio	-1.71	-1.11	-1.01	-1.39	-2.28	1.18
Net Debt / EBITDA Ratio	-0.50	-0.50	-2.63	-1.75	-0.75	-0.31
Net Debt / FCF Ratio	-0.45	-0.44	-4.07	-1.89	-1.44	-0.32
Asset Turnover	0.17	0.51	0.03	0.03	0.29	0.34
Inventory Turnover	1.31	3.86	0.08	0.07	2.10	1.54
Quick Ratio	0.58	0.19	0.08	0.34	0.47	0.73
Current Ratio	0.90	0.43	0.34	0.49	0.61	0.94
Return on Equity (ROE)	-	-	-	-	-	-402.40%
Return on Assets (ROA)	-52.58%	-56.84%	-37.06%	-36.77%	-53.91%	-67.14%
Return on Capital Employed (ROCE)	-316.80%	-4414.80%	64.30%	479.10%	-340.90%	-198.20%
Earnings Yield	-44.84%	40.31%	-47.73%	-34.62%	-25.87%	-24.44%
FCF Yield	-41.36%	-27.34%	-19.83%	-27.17%	-13.91%	-26.08%
Buyback Yield / Dilution	-34.53%	-22.23%	-5.32%	-7.20%	-3.67%	-31.97%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.